Pathology - Research and Practice, Journal Year: 2024, Volume and Issue: 263, P. 155619 - 155619
Published: Sept. 28, 2024
Language: Английский
Journal of Cancer Research and Clinical Oncology, Journal Year: 2025, Volume and Issue: 151(2)
Published: Feb. 21, 2025
Swiss healthcare institutions conducted only urgent procedures during the COVID-19 lockdown, potentially leading to a lack of care for other severe diseases, such as cancer. We examined effects pandemic on cancer stage distribution and time between diagnosis treatment initiation using population-based registry data. The study was based data cantons Zurich Zug from 2018 2021. Cancer analysed descriptively with Pearson's Chi-squared test. Time determined in days by fitting Quasipoisson regression models. For all-cancer colorectal, lung, prostate statistically significant evidence difference stages among incidence years observed. Based models, longer (TTI) observed patients diagnosed 2021 receiving surgery (Rate Ratio = 1.08 [95% confidence interval 1.03, 1.14]) or hormone therapy (1.20 [1.03, 1.40]) compared those 2018/19 therapies. no TTI 2020 any therapies investigated, except chemotherapy shorter (0.92 [0.86, 0.98]). outcomes coincided beginning Switzerland onwards. Short- long-term public system were However, we cannot exclude that implementation new law registration explains part our observations.
Language: Английский
Citations
0
Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 179, P. 117282 - 117282
Published: Aug. 14, 2024
Salvia miltiorrhiza Bunge extracts, known for their diverse biological activities, often have remarkable efficacy in treating pulmonary diseases overlooked due to specific cardiovascular actions. With the recent outbreak of COVID-19, research into pulmonary-related has garnered significant attention. extracts can be broadly categorized lipophilic and hydrophilic components; however, a comprehensive summary mechanisms is lacking. Therefore, this review aims systematically summarize therapeutic 10 major fibrosis, lung cancer, acute injury, chronic obstructive disease, with goal identifying promising options efficacious therapies.
Language: Английский
Citations
2
Cancers, Journal Year: 2024, Volume and Issue: 16(14), P. 2586 - 2586
Published: July 19, 2024
This was a retrospective study of the profile and initial treatments adults diagnosed with early-stage (ES) non-small cell lung cancer (NSCLC) during January 2018–December 2021 at 16 leading hospital institutions in Austria, excluding patients enrolled clinical trials. In total, 319 were planned ~1:1:1 ratio across StI:II:III. Most tested biomarkers programmed death ligand 1 (PD-L1; 58% expressing), Kirsten rat sarcoma virus (KRAS; 22% positive), epidermal growth factor receptor (EGFR; 18% positive). Of 115/98/106 StI/II/III patients, 82%/85%/36% underwent surgery, followed by systemic therapy 9%/45%/47% those [mostly chemotherapy (ChT)]. Unresected treated StIII received ChT + radiotherapy [43%; immune checkpoint inhibitors (ICIs) 39% those], ICI ± (35%), ChT-alone/radiotherapy-alone (22%). Treatment initiated median (interquartile range) 24 (7–39) days after histological confirmation, 55 (38–81) first medical visit. Based on exploratory analyses all newly any stage NSCLC 2018–2021 14 sites (N = 7846), 22%/10%/25%/43% had StI/II/III/IV. The total number not significantly different between pre-COVID-19 (2018–2019) study-specific COVID-19 (2020–2021) periods, while StI proportion increased (21% vs. 23%; p 0.012). Small differences noted treatments. conclusion, aligned guideline recommendations time which preceded era ICIs targeted therapies (neo)adjuvant setting.
Language: Английский
Citations
1
Pathology - Research and Practice, Journal Year: 2024, Volume and Issue: 263, P. 155619 - 155619
Published: Sept. 28, 2024
Language: Английский
Citations
0